KalVista Pharmaceuticals : Corporate Presentation May 2025

Published: 2025-05-13 19:50:04 ET KALV

Published on 05/13/2025 at 19:50

May 2025

A monumental year for KalVista and the HAE community

Major milestones anticipated to drive growth

March 2025

Enrollment completed

in pediatric trial

2H 2025

Germany Launch

2026+

Rest of world & partner launches

June 2025

FDA PDUFA & US launch

1H 2026

UK & Japan launches

3

Sebetralstat has the potential to become the foundational treatment for HAE

First and only oral on-demand treatment, if approved

CURRENT GLOBAL HAE MARKET

Poised to transform the HAE treatment landscape

GLOBAL ON-DEMAND OPPORTUNITY

4

Disclaimer

Kalvista Pharmaceuticals Inc. published this content on May 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2025 at 23:49 UTC.